- News
News
Welcome to the homepage of AIHTA!
AIHTA is an academic non-profit institute. At our website we wish to present our research and give support for health care decision-making. Here all of our reports are available for free. For further information please contact the AIHTA team.
In the News section you will find our most recent publications: newsletter, project-reports etc. Previous reports you might find via Research areas, Research projects and Repository.
Announcement
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce you four new Fact Sheets.
Fact Sheet No. 180 (June 2024)
Erdafitinib (Balversa®) as monotherapy for the treatment of unresectable or metastatic urothelial carcinoma (UC)
Fact Sheet No. 181 (June 2024)
Odronextamab (Ordspono®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (r/r FL) or diffuse large B?cell lymphoma (r/r DLBCL)
Fact Sheet No. 183 (June 2024)
Epcoritamab (Tepkinly®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (FL)
Announcement
Stereotactic radiotherapy, proton therapy and irreversible electroporation for the treatment of localised prostate cancer
This update report assesses three alternative treatments to radical therapies for localised prostate cancer (PCA): irreversible electroporation (IRE) uses electrode needles to target and destroy carcinoma tissue; stereotactic radiation therapy (SBRT) and proton therapy (PT) are forms of external beam radiation therapy, SBRT delivers high dose radiation in fewer fractions than conventional or moderate fractionation radiation, while PT delivers high-dose ionizing radiation with great precision.
The current evidence remains insufficient to conclude that IRE, SBRT, and PT improve outcomes in terms of survival and quality of life, as well as the avoidance of radical invasive procedures like prostatectomy, compared to conventional therapies. Recent RCTs on SBRT show minor differences in survival rates compared to conventional fractionation radiation in low- and intermediate-risk PCa. Further research is necessary for definitive conclusions.
Publication: Project Report No.: 107/1. Update: https://eprints.aihta.at/1530/
Contact: Judit Erdös
Newsletter
Note: this content is only available in German.
Inhalt
- Editorial: HTA-Patient*innenschulungen in EUCAPA
- Thermoablation von benignen Schilddrüsenknoten
- Perkutane transluminale Koronarangioplastie mit medikamentenbeschichtetem Ballon bei koronarer Herzkrankheit
- Elektrokonvulsionstherapie bei therapieresistenter Depression und therapieresistenter Schizophrenie
- Renale Denervierung bei therapieresistenter Hypertonie
- Perkutaner transfemoraler heterotoper Trikuspidalklappenersatz bei Trikuspidalinsuffizienz
- Termine
- Themen-Vorschau
Announcement
Evaluation of individual medical procedures - Reports 2024
We are pleased to introduce our new reports.
Decision Support Documents 2024:
- DSD 139: Caval valve implantation for severe tricuspid regurgitation https://eprints.aihta.at/1525
- DSD 140: Electroconvulsive therapy in treatment-resistant depression and treatment-resistant schizophrenia https://eprints.aihta.at/1526
- DSD 141: Thermoablation for benign thyroid nodules https://eprints.aihta.at/1527
+ 2 Updates
- DSD 24: Percutaneous transluminal coronary angioplasty (PTCA) with drug-eluting balloon (DEB) in patients with coronary artery disease (CAD). 3. Update 2024 https://eprints.aihta.at/1528
- DSD 45: Renal denervation (RDN) in patients with treatment resistant hypertension. 2. Update 2024 https://eprints.aihta.at/1529
Announcement
Point of Care Tests (POCT): D-Dimer and Troponin. Update 2024
Point of care tests (POCTs) for troponin (Tn) and D-Dimer enable rapid diagnostics near patients. Tn-POCTs are used when there is a suspicion of acute coronary syndrome (ACS) and D-Dimer-POCTs are used when there is a suspicion of venous thromboembolism (VTE).
The aim of this report is to evaluate the clinical utility of the two POC diagnostics, D-Dimer and troponin, in primary care.
Publication: HTA Project Report No. 124, 1. Update 2024: https://eprints.aihta.at/1524/
Contact: Claudia Wild
Announcement
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce you three new Fact Sheets.
Fact Sheet No. 177 (May 2024)
Sugemalimab (Cejemly®) with platinum-based chemotherapy for the first?line treatment of metastatic non-small-cell lung cancer (NSCLC)
Fact Sheet No. 178 (May 2024)
Osimertinib (Tagrisso®) with pemetrexed and platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer (NSCLC)
Fact Sheet No. 179 (May 2024)
Tislelizumab (Tevimbra®) monotherapy or in combination with chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)
Newsletter
Note: this content is only available in German.
Inhalt
- Editorial: Neue Methoden aus der Gesundheitsökonomie machen Auswirkungen neuer Leistungen auf gesundheitliche Ungleichheit sichtbar
- Pharmakogenetik: personalisierte Verschreibungen
- Hautkrebsprävention: Leitlinien-Empfehlungen zur Primär- und Sekundärprävention
- Gentests bei familiärer Hypercholesterinämie
- Fernüberwachung bei chronischen körperlichen Erkrankungen
- Termine
- Themen-Vorschau
Announcement
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce you six new Fact Sheets.
Fact Sheet No. 171 (April 2024)
Fruquintinib (Fruzaqla®) as monotherapy for the treatment of metastatic colorectal cancer (mCRC)
Fact Sheet No. 172 (April 2024)
Capivasertib (Truqap®) with fulvestrant for the treatment ER-positive, HER2 negative locally advanced or metastatic breast cancer
Fact Sheet No. 173 (April 2024)
Alectinib (Alecensa®) as adjuvant treatment following complete tumour resection for adult patients with ALK positive non-small cell lung cancer (NSCLC)
Fact Sheet No. 174 (April 2024)
Nivolumab (Opdivo®) in combination with cisplatin and gemcitabine for the first-line treatment of unresectable or metastatic urothelial carcinoma
Fact Sheet No. 175 (April 2024)
Entrectinib (Rozlytrek®) as monotherapy for the treatment of solid tumours with a NTRK gene fusion
Fact Sheet No. 176 (April 2024)
Amivantamab (Rybrevant®) with carboplatin and pemetrexed for the first line treatment of advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations
Newsletter
Note: this content is only available in German.
Inhalt
- Editorial: AIHTA-Framework erleichtert Identifikation öffentlicher Beiträge zur Entwicklung von Innovationen im Gesundheitswesen
- Biofeedback-Therapie bei Migräne
- Preis- und Kostenentwicklung von Orphan Drugs
- Modelle der primären Gesundheitsversorgung für Obdachlose
- CAR-basierte Immuntherapie mit Fokus auf CAR-NK-Zellen
- Termine
- Themen-Vorschau
Project / Prevention and screening, Psychological & psychiatric interventions
Strategies to reduce weight stigmatisation of people with overweight or obesity in the healthcare sector
Project leaders: Sarah Wolf
Project team: Sarah Wolf, Julia Kern
Duration: Mid-April 2024 until Mid-November 2024
Language: German (with English executive summary)
Publication: HTA Project Report No. 160: https://eprints.aihta.at/1547/
